Moreover, genetic mutations in the PIK3CA/AKT/mTOR pathway, one of the EGFR downstream pathways, might impact the response to EGFR-TKI in NSCLC with activating EGFR mutations [51]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.